SAB Biotherapeutics Chief Operating Officer, Dr. Christoph Bausch, to Present at the Large Animal Genetic Engineering Summit
31 May 2022 - 10:30PM
SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage
biopharmaceutical company with a novel immunotherapy platform that
produces specifically targeted, high-potency, fully human
polyclonal antibodies without the need for human donors, today
announced its participation at the Large Animal Genetic Engineering
Summit (LAGE) taking place June 5-8, 2022, in Park City, Utah. SAB
Chief Operating Officer, Dr. Christoph Bausch, will present as part
of the summit’s “Gene Editing to Improve Human Health” track.
The presentation, titled “Leveraging Genetically Engineered
Ungulates to Produce Novel Human Biotherapeutics,” will highlight
SAB’s novel immunotherapy platform of Transchromosomic (Tc) Bovine™
(genetically engineered cattle) that can consistently and reliably
produce fully human antibodies without the need for convalescent
plasma from human donors. Dr. Christoph Bausch will introduce a
range of topics, including an overview of SAB’s DiversitAb™
platform centered around Tc Bovine and an overview of SAB’s
pipeline programs that include SAB-185, the company’s
anti-SARS-CoV-2 therapeutic; SAB-176, the company’s seasonal
influenza therapeutic; and SAB-142, the company’s Type 1 diabetes
and organ transplantation therapeutic. Additionally, he will
discuss the potential that SAB’s novel immunotherapy platform has
to expand into personalized medicine through the development of
Transchromosomic (Tc) Goats™.
“SAB has made incredible strides in genetic engineering with our
Tc Bovine platform that produces fully human antibodies, and I am
excited to share the progress our novel technology has made in
developing the Tc Goat that also expresses fully human antibodies,”
Dr. Christoph Bausch said. “I’m honored to be taking the stage at
this year’s LAGE Summit and look forward to providing insights from
the SAB platform, and, ultimately, contributing to the scientific
community’s knowledge and understanding of the tremendous potential
that human polyclonal antibodies have in immunotherapy.”
Dr. Christoph Bausch is an experienced research scientist and
biomanufacturing executive who has led the successful discovery,
development, and commercialization of platform technologies in the
life sciences. At SAB, he oversees the drug discovery, development,
and manufacturing operations and leads all pipeline programs,
including SAB-185 (anti-SARS-CoV-2), SAB-176 (seasonal influenza)
and SAB-142 (Type 1 diabetes and organ transplantation) programs.
SAB-185 is a COVID-19 therapeutic candidate and represents a
treatment option that provides a highly specific match against the
complexity, diversity and the mutations SARS-CoV-2 presents.
SAB-176 is a polyclonal antibody therapeutic candidate recently
evaluated in a Phase 2a Challenge study for the treatment of
seasonal influenza. SAB-142 is a fully human anti-thymocyte
globulin therapeutic candidate for Type 1 diabetes and organ
transplantation (induction/rejection) currently in preclinical
development.
Presentation Title: |
|
“Leveraging Genetically Engineered Ungulates to Produce Novel
Human Biotherapeutics” |
Presenter: |
|
Christoph Bausch, Ph.D., Chief Operating Officer, SAB
Biotherapeutics |
Session: |
|
Gene Editing to Improve Human Health |
Session Date / Time: |
|
Tuesday, June 7, 10:40 – 11:20 AM MDT |
About SAB Biotherapeutics, Inc.SAB
Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical
company advancing a new class of immunotherapies leveraging fully
human polyclonal antibodies with a focus on building a leading
immune and autoimmune disorders pipeline. SAB has applied advanced
genetic engineering and antibody science to develop
transchromosomic (Tc) Bovine™ that produce fully human antibodies
targeted at specific diseases, including infectious diseases such
as COVID-19 and influenza, immune and autoimmune disorders
including type 1 diabetes and organ transplantation, and cancer.
SAB’s versatile DiversitAb™ platform is applicable to a wide range
of serious unmet needs in human diseases. It produces natural,
specifically targeted, high-potency, human polyclonal
immunotherapies. SAB currently has multiple drug development
programs underway and collaborations with the US government and
global pharmaceutical companies. For more information on SAB,
visit: https://www.SAb.bio/ and follow @SABBantibody on
Twitter.
Forward-Looking StatementsCertain statements
made herein that are not historical facts are forward-looking
statements for purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995. Forward-looking
statements generally are accompanied by words such as “believe,”
“may,” “will,” “estimate,” “continue,” “anticipate,” “intend,”
“expect,” “should,” “would,” “plan,” “predict,” “potential,”
“seem,” “seek,” “future,” “outlook” and similar expressions that
predict or indicate future events or trends or that are not
statements of historical matters. These forward-looking statements
include, but are not limited to, statements regarding future
events, including the development and efficacy of SAB-185, our
influenza program and other discovery programs, our cash runaway
into 2023 and potential future government and third-party
collaborations or funded programs.
These statements are based on the current expectations of SAB
and are not predictions of actual performance. These
forward-looking statements are provided for illustrative purposes
only and are not intended to serve as, and must not be relied on,
by any investor as a guarantee, an assurance, a prediction or a
definitive statement of fact or probability. Actual events and
circumstances are difficult or impossible to predict, will differ
from assumption and are beyond the control of SAB. A further
description of risks and uncertainties can be found in the
prospectus filed by SAB Biotherapeutics, Inc. on December 29, 2021,
including in the sections thereof captioned “Risk Factors” as well
as in its subsequent reports on Form 10-K, 10-Q and Form 8-K, all
of which will be filed with the U.S. Securities and Exchange
Commission and available at https://www.sec.gov/
Media Relations Contact
SAB PR TeamSAbPR@westwicke.com
SAB Biotherapeutics (NASDAQ:SABSW)
Historical Stock Chart
From Jun 2024 to Jul 2024
SAB Biotherapeutics (NASDAQ:SABSW)
Historical Stock Chart
From Jul 2023 to Jul 2024